Anxiety disorder

#Anxiety disorder #Neuropsychiatric disorders #Phase I trial #Seaport Therapeutics

First patient dosed in Seaport’s anxiety clinical trial

Biopharmaceutical company Seaport Therapeutics has announced that the first patient has been dosed in a Phase I clinical trial of its treatment for generalised anxiety disorder.   Seaport’s GlyphAgo is an oral prodrug of agomelatine, which is a clinically validated melatonin receptor agonist and serotonin 2C receptor antagonist. Read More

#News

gut epithelium
#Antidepressants #Anxiety disorder #Depression #Gut-brain interaction #Pregnancy

Could the gut epithelium be a new target for antidepressants?

Researchers have discovered new connections between the gut and brain that hold promise for more targeted treatments for depression and anxiety.  The findings could also help prevent digestive issues in children by limiting the transmission of antidepressants during pregnancy.   The study,… Read More

#News #Trending News

Neurons
#Anxiety disorder #Neurology #Neuroscience #Tokyo University of Science

Scientists identify potential new therapeutic target for anxiety

A new study has highlighted the role of specific neuronal circuits in the brain involved in the development of anxiety, and distinct mechanisms of action of the therapeutic delta opioid receptor (DOP) agonist KNT-127. Understanding the neural circuits and molecular mechanisms that trigger anxiety can aid… Read More

#News

Mental health
#Antidepressants #Anxiety disorder #Depression #Drug discovery #Mental health #Neuroscience #Psychiatry

World Wellbeing Week 2023: Celebrating drug discovery innovation

DDW’s Diana Spencer provides an overview of the latest innovations in drug discovery for mental health. World Wellbeing Week was created to celebrate the many aspects of wellbeing, from meaningful, purposeful work to financial security, physical, mental and emotional health, social resilience and empathic corporate and civic leadership, community relations… Read More

#Exclusive Content

#Anxiety disorder #Diabetes #Drug development #Drug discovery #Geographic atrophy #HIV #Lung cancer #Oncology

Podcast: This week’s drug discovery highlights

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  Each of our top five stories this week exemplify the scientific curiosity that fuels the drug… Read More

#News

#Anxiety disorder #Diabetes #Drug development #Drug discovery #Geographic atrophy #HIV #Lung cancer #Oncology

This week in drug discovery (24-28 April)

News round-up for 24-28 April by DDW Digital Content Editor Diana Spencer. Each of our top five stories this week exemplify the scientific curiosity that fuels the drug discovery sector, ultimately leading to better treatments for patients. The stories cover the efforts by research teams to… Read More

#News

Amygdala
#Anxiety disorder #Drug discovery #Neuroscience #Preclinical investigations #University of Bristol #University of Exeter

Discovery represents the ‘first step’ to better anti-anxiety drugs

A team of scientists have discovered that modification of a gene in the brain can reduce anxiety levels, offering an exciting novel drug target for anxiety disorders. The discovery, led by researchers at the Universities of Bristol and Exeter in the UK, is published in Nature… Read More

#News

#Anxiety disorder #Biotherapeutics #Neuroscience #Postpartum depression

Potential treatment for anxiety and postpartum depression 

PureTech Health, a clinical-stage biotherapeutics company, will advance therapeutic candidate LYT-300 (oral allopregnanolone) for the potential treatment of anxiety disorders and postpartum depression (PPD).    A social anxiety clinical trial in healthy volunteers is expected to begin in the first half of 2023, with results anticipated by the… Read More

#News